ADXS - Advaxis, Inc.

NasdaqGS - NasdaqGS Delayed Price. Currency in USD

Advaxis, Inc.

305 College Road East
Princeton, NJ 08540
United States
609-452-9813
http://www.advaxis.com

SectorHealthcare
IndustryBiotechnology
Full Time Employees108

Key Executives

NameTitlePayExercisedAge
Ms. Sara M. BonsteinExec. VP, Principal Accounting Officer, CFO & Corp. Sec.1.01MN/A37
Dr. Robert G. Petit Ph.D.Exec. VP & Chief Scientific Officer1.29MN/A58
Mr. Anthony A. LombardoInterim Chief Exec. OfficerN/AN/A69
Mr. Christopher DukeSr. VP & COON/AN/AN/A
Mr. Mayo PujolsSr. VP of Technical OperationsN/AN/AN/A
Amounts are as of December 31, 2016 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.

Description

Advaxis, Inc., a clinical stage biotechnology company, focuses on the discovery, development, and commercialization of Listeria monocytogenes (Lm) technology based immunotherapies in the United States. It is developing Axalimogene filolisbac and ADXS-Dual that are Lm-LLO immunotherapy product candidates for the treatment of human papilloma virus associated cancers, including cervical, and head and neck cancers. The company is also developing Axalimogene filolisbac for the treatment of anal cancer; ADXS-PSA, an Lm-LLO immunotherapy product candidate, which is designed to target the prostate specific antigen associated with prostate cancer; and ADXS-NEO, an individualized Lm technology antigen delivery product candidate that is designed to create individualized therapies by activating the patient's immune system to respond against multiple mutations or neoantigens. In addition, it is developing ADXS-HOT for generating potent anti-cancer immunity; and ADXS-HER2, an Lm technology antigen delivery product candidate that is designed to target HER2 expressing solid tumors, including human and canine osteosarcoma. The company has collaboration and licensing agreements with Bristol-Myers Squibb Company; Amgen Inc.; Sellas Life Science Group; Merck & Co., Inc.; MedImmune/AstraZeneca PLC; Especificos Stendhal SA de CV; Aratana Therapeutics Inc.; and Global BioPharma Inc. Advaxis, Inc. was founded in 2002 and is based in Princeton, New Jersey.

Corporate Governance

Advaxis, Inc.’s ISS Governance QualityScore as of January 1, 2018 is 9. The pillar scores are Audit: 2; Board: 8; Shareholder Rights: 2; Compensation: 10.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while a 10 indicates higher governance risk.